ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

ARK Investment Management LLC raised its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 6.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,101,038 shares of the biotechnology company's stock after purchasing an additional 136,074 shares during the quarter. ARK Investment Management LLC owned 7.80% of Arcturus Therapeutics worth $48,765,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ARCT. Russell Investments Group Ltd. acquired a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at $40,000. nVerses Capital LLC acquired a new stake in shares of Arcturus Therapeutics in the 3rd quarter valued at $42,000. Quest Partners LLC boosted its holdings in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock valued at $90,000 after purchasing an additional 3,579 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock valued at $121,000 after purchasing an additional 2,038 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter valued at $142,000. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Trading Up 4.7 %

NASDAQ:ARCT traded up $0.89 during trading hours on Friday, hitting $19.63. 386,587 shares of the company were exchanged, compared to its average volume of 466,985. The company has a fifty day simple moving average of $20.61 and a 200 day simple moving average of $24.26. Arcturus Therapeutics Holdings Inc. has a one year low of $17.26 and a one year high of $45.00. The stock has a market capitalization of $528.54 million, a price-to-earnings ratio of -8.84 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The firm had revenue of $49.86 million during the quarter, compared to analyst estimates of $21.00 million. During the same period last year, the company posted ($1.98) EPS. Equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ARCT. HC Wainwright reiterated a "buy" rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research note on Friday. Leerink Partnrs upgraded Arcturus Therapeutics to a "strong-buy" rating in a research note on Monday, August 12th. Leerink Partners began coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an "outperform" rating and a $70.00 price target for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $71.40.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 12,000 shares of the firm's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 15.30% of the company's stock.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.